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Expression of HOX transcript antisense intergenic RNA (HOTAIR), a large intergenic noncoding RNA
(lincRNA), has been described as a metastases-associated lincRNA in various cancers including breast, liver
and colon cancer cancers. We sought to determine if expression of HOTAIR could be used as a surrogate for
assessing nodal metastases and evaluated RNA in situ hybridization (RNA-ISH) assay in a tissue microarray
constructed from 133 breast cancer patients. The prognostic value of HOTAIR was further validated in large
cohorts using The Cancer Genome Atlas (TCGA) breast cancer subjects. RNA-ISH analysis was successful in
94 cases (17% cases scored 0, 32.9% scored 1, 30.8% scored 2, and 19.1% scored 3). The expression of
HOTAIR did not correlate with nodal metastasis regardless of the scoring intensity or with other study
parameters (age, tumor size and grade, expression status). Further analysis of TCGA dataset showed that
HOTAIR expression was lower in ductal carcinomas but higher in ER-negative tumors. Overexpression of
HOTAIR was not associated with nodal metastases or prognosis in ER-positive patients. Its function as a
poor prognostic indicator in ER-negative patients was restricted to node-positive patients. HOTAIR appears
to be a marker for lymphatic metastases rather than hematogenous metastases in ER-negative patients.
R
ecent studies have shown that the idea ofDNA transcription resulting in synthesis of corresponding protein
is rather simplistic1. A number of additional factors are involved in the control of the transcription process.
RNAs do not appear to be simple messengers but are complex species with many distinct functional
subtypes. Next generation sequencing studies have estimated that 98% of the DNA is noncoding; these RNAs
derived from noncoding regions have a variety of functions that include gene regulation2,3. Among the different
classes of noncoding (ncRNAs), microRNAs have been the most extensively investigated4. In addition to
microRNAs, long noncoding RNAs (lncRNAs) constitute another species of RNAs. LncRNAs are defined as
transcribed RNA molecules that are longer than 200 nucleotides and have no obvious protein coding capacity5.
They are more tissue specific than protein coding genes6. The abundance of lncRNAs in the genome, their
association with the myriad of different disease phenotypes, and their diverse cellular roles are drawing the
attention of the scientific community7–15. However, knowledge regarding the actual number of functional
lncRNAs and the mechanism(s) by which they carry out their functions is still limited. Recent advances in
RNA sequencing (RNA-seq) and computational methods have revealed that large intergenic noncoding RNAs
(lincRNAs) are the largest class of lncRNAmolecules in the human genome5. At least 8000 human lincRNAs have
been identified5. Biological characterization studies suggest that many lincRNAs act as scaffolds that regulate
molecular (protein, RNA, and DNA) interactions required for various signaling networks. It has been estimated
that at least 30% of lncRNAs are bound to the polycomb repressive complexes and target these chromatin-
modifying complexes to the target genes16.
Gupta et al hybridized RNA from normal breast epithelia, primary tumors, and distant metastases to ultrahigh
density HOX tiling array17. They found 170 ncRNAs and 63 HOX exons that were differentially expressed.
HOTAIR (HOX antisense intergenic RNA) was one of the metastases associated lincRNAs. Rinn et al and
Woo and Kingston et al had previously identified its role in regulating HOX genes18,19. HOTAIR is a large
noncoding RNA which is 2158-nucleotides long, and expressed from the HOXC locus on chromosome
12q13.1318. It contains 59 and 39 domains. The 59 domain binds to PRC2, while the 39 domain interacts with
the LSD1/Co-REST/REST complex to coordinately regulate histone H3 lysine 27 methylation and lysine 4
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et al further showed by qPCR that HOTAIR is overexpressed 100–
2000 fold in breast cancer metastases17. Its expression was sometimes
high but heterogeneous in primary tumors. The expression was a
significant predictor of metastases and death in a series of 132 breast
cancer patients with extensive followup.
Since the original publication, HOTAIR has been shown to be a
poor prognostic factor in a number of cancers including breast, lung,
colon, liver and gastrointestinal stromal tumors17,21–24. Its expression
has been linked to increased cancer cell invasiveness and epithelial-
to-mesenchymal transformation25. Gain-of-function studies show
that the activities of hundreds of genes (such as the HOXD locus,
progesterone receptor, cell adhesion molecules) are inhibited, while
dozens of other genes (such as ABL2, SNAIL, and LAMB3) are acti-
vated17. An in vitro functional study showed that HOTAIR overex-
pression in four different breast cancer cell lines could promote
colony growth and invasion17. Animal experiments demonstrated
that the breast cancer cell line, MDA-MB-231, which expressed
HOTAIR, grew quickly in primary tumor foci with increased meta-
static potential to the lung17.
Given the purported importance of HOTAIR in breast cancer, we
sought to address the question of whether the expression ofHOTAIR
could be used as a surrogate for assessing nodal metastases. We
additionally analyzed the impact of high levels of HOTAIR on nodal
metastases and overall survival in The Cancer Genome Atlas
(TCGA) dataset.
Results
In situ HOTAIR Expression in Breast Cancer TMA Cohort. The
expression of HOTAIR was analyzed in 94 of the 133 cases by RNA-
ISH based on the eligibility criteria. These criteria included the
presence of at least 100 tumor cell nuclei. Thirty-nine cases were
excluded due to lack of adequate tumor cells, folds in tissue
sections, or loss of tissue during processing.
Consistent with prior descriptions, the signals were scattered in
the cell and were not restricted to the nucleus26. Similarly, very few, if
any, signals were identified in the nontumor stromal cells—high-
lighting the tissue-specific distribution of this lincRNA. The signals
were absent or rare (less than 1 per 100 tumor nuclei) in 16 cases
(17%); one to 10 signals per 100 nuclei in 31 cases (32.9%), 10 to 100
signals in 29 (30.8%), and innumerable in 18 cases (19.1%).
Representative images of HOTAIR microRNA signals are shown in
Figure 1A–C for each scoring category. The expression of HOTAIR
did not correlate with nodal metastasis regardless of the scoring
intensity used as a cutoff point (Table 1). It also did not correlate
with other parameters such as age (categorical 50 versus . 50),
tumor size and grade, and ER and HER2 status.
Confirmation of the Prognostic Value of HOTAIR in Breast
Cancer Using TCGA Breast Invasive Carcinoma Dataset. To
assess the prognostic value of HOTAIR expression in breast
tumors, we next analyzed its correlation with overall survival using
TCGA data of breast cancer subjects. The expression of HOTAIR in
these subjects was categorized based on the low (n5 476; black line)
and high (n5 476; red line) expressions using themedian expression
as a cutoff (Figure 2A–B). The higher HOTAIR expression was
associated with shorter overall survival in ER-negative breast
cancer patients (P 5 0.018) (Figure 2B). In the cohort with high
HOTAIR levels, the overall survival probability was 60% and 46.4%
at 50 and 100 months, respectively, and those with low HOTAIR
levels showed a survival probability of 86% and 62.8% at 50 and
100 months, respectively. On the other hand, HOTAIR levels were
not associated with overall survival in ER-positive breast cancer (P5
0.41) (Figure 2A).
We further assessed the correlation of HOTAIR expression with
overall survival and lymph node status using TCGA dataset. High
expression ofHOTAIRwas not associated with a greater likelihood of
nodal metastases. Further subset analysis of the nodal involvement
showed significance only in extensive node positivity (N3) when
compared with N0 (P 5 0.0049) and N1 (P 5 0.00035) (Figure 3).
In TCGA dataset,HOTAIRwas not associated with prognosis in ER-
positive patients (node positive and negative). High levels were found
to be associated with worse prognosis in ER-negative/ node–positive
patients (P 5 0.02) but not in node-negative patients (P 5 0.2)
(Figure 4A–D).
Discussion
Metastasis is the leading cause of breast cancer mortality. The pre-
vention and treatment of metastasis, however, remains a significant
clinical challenge. The spread of breast tumors to local and regional
lymph nodes is an important means of tumor dissemination. The
presence and the number of involved lymph nodes remains the single
best indicator of whether or not the cancer has become widely meta-
static. Identification of the underlying molecular mechanisms of
lymph node metastasis and a better understanding how to modulate
these will be a significant step in the goal of prevention of metastases.
Recent studies have shown that lincRNA is a novel class of mole-
cules that regulates cancer progression and metastasis27. LincRNAs
can serve as scaffolds to control chromatin states and epigenetic
changes17,20. LincRNA HOTAIR was shown to regulate metastatic
progression by reprogramming the chromatin state17,20. The high
expression of HOTAIR was a significant predictor with poor pro-
gnosis and metastasis in breast carcinomas17. Further analysis per-
formed by the same group showed that HOTAIR was also increased
in the metastatic carcinomas when compared in matched primary
and metastatic cancers26. A separate study foundHOTAIR expression
Figure 1 | Expression of HOTAIR in a series of breast cancer samples.
Expression levels were depicted as (A) 1–10 signals, (B) 10–100 signals, and
(C) multiple signals per cell.
Table 1 | Clinicopathological characteristics of the 94 cases that
were analyzable for the expression of HOTAIR
Negative (0 or 1) Positive (2–3) P value
Premenopausal 16 15 1
Postmenopausal 31 32
Tumor size # 2 cm 27 34 0.194
Tumor size . 2 cm 20 13
Grade 1 12 14 0.902
Grade 2 19 17
Grade 3 16 16
IDC 37 41 0.557
ILC 5 3
Others 5 3
Node-negative 28 34 0.276
Node-positive 19 13
ER-negative 10 13 0.632
ER-positive 37 34
HER2-negative 40 7 1
HER2-positive 39 8
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.
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to be an important independent indicator for predicting metastasis,
especially in ER-positive breast cancer patients28.
The current study investigated the role of HOTAIR expression in
relation to nodal metastases in a breast cancer TMA cohort. Using
RNA-ISH, in situ overexpression ofHOTAIRwas not associated with
nodal metastases. We also did not observe any association with age,
tumor grade, ER, andHER2. The difference in observed results could
be due to a number of parameters including assay methods and size
of cohort including the number of ER-positive cases. In the original
study, Gupta et al identified increased HOTAIR expression in prim-
ary and metastatic breast cancers using RT-PCR based methods17.
The same group (Chisholm et al) developed an in situ hybridization
assay using well-established cell line controls26. In this followup
study, they observed a trend of higher HOTAIR expression in the
metastatic than in the primary breast cancers. Importantly, they
could not confirm the survival data reported in the original study.
However, based on the analysis of only 6 patients of the original 243
cases, they reported a trend for tumors overexpressing EZH2 and
HOTAIR to have a poor prognosis. Sorensen et al analyzed the
expression of HOTAIR in a case control design study using an
Agilent-based microarray platform28. They found high HOTAIR
expression in primary tumors from patients who developed meta-
stases as opposed to patients who did not. The association was sig-
nificantly in patients with ER-positive tumors, but not in ER-negative
tumors28. Lu et al analyzed the expression of HOTAIR in a series of
348 patients using quantitative RT-PCR22. They did not find a sig-
nificant association ofHOTAIR expression with prognosis in univari-
ate analysis. These studies together indicate that the differences
observed cannot be entirely explained by assay method variability.
The size of the cohort and the distribution of cases based on
molecular classification and nodal positivity could explain some of
the observed differences. To circumvent these issues, we analyzed the
expression of HOTAIR in TCGA dataset (n5 952) and correlated it
with nodal metastases and overall survival. Consistent with our in
situ hybridization data, high HOTAIR expression in the entire data-
set was not associated with nodal involvement (P 5 0.33). High
HOTAIR was associated with worse outcome in patients with ER-
negative breast tumors (P5 0.018), but not in ER-positive patients (P
Figure 2 | Impact of HOTAIR expression on survival in The Cancer Genome Atlas dataset (n5 952). KM plots show that HOTAIR expression above
median is associated with poor outcome in ER-negative patients (A) but not in ER-positive patients (B).
Figure 3 | Correlation of HOTAIR expression with nodal status using The Cancer Genome Atlas dataset. Comparison of the cases by nodal status
revealed only significant association between N3 versus N0 (P 5 0.005) or N1 (P 5 0.003). Other comparisons were not significant.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8765 | DOI: 10.1038/srep08765 3
5 0.41). This observation is in contrast to the results reported by
Sorensen et al but are similar to those reported by Lu et al28,29. Some of
the differences could be explained by the size of the cohorts, relative
proportions of ER-positive and ER-negative patients, and the end-
points used. The endpoint in the current study is overall survival
while many of the studies used distant metastases-free survival.
Association of high HOTAIR expression was observed with poor
overall survival in ER-negative tumors; interestingly, this was observed
only with patients having nodal metastases. It has been well documen-
ted that nodal involvement in triple-negative tumors is less prognostic
in ER-negative tumors as opposed to ER-positive tumors. Several
studies have reported that triple-negative cancers have less nodal
metastasis, although the tumors are categorized as high grade30–33.
It is thus possible that the high expression of HOTAIR in ER-
negative tumors could be an indicator of activation of pathways
associated with lymphatic metastases rather than vascular metastases.
A strong association was seen between HOTAIR expression and
histology. Ductal carcinomas (not otherwise specified) were less
likely to have high levels ofHOTAIR compared to special histological
types such as lobular carcinomas (P , 0.00001). This finding is
somewhat in variance with the high expression seen in ER-negative
tumors.
In summary, our study shows that the prognostic role ofHOTAIR
expression is more or less restricted to ER-negative, lymph node–
positive tumors, where its expression could possibly be used as a
potential prognostic marker identifying patients at greater risk for
poor overall survival. It does not seem to be useful in prognostication
of ER-positive breast cancer or identification of patients likely to have
nodal metastases. Given the well-recognized followup limitations of
TCGA cohort, further studies are necessary to clarify the role of
HOTAIR in metastases in cohorts well annotated for tumor his-
tology, nodal status, and survival information.
Figure 4 | Kaplan–Meier overall survival in regards to HOTAIR expression and nodal status. Expression above median is not associated with poor
outcome in ER-positive (regardless of lymph node status) (A&B). In ER-negative cases (C&D), highHOTAIRwas only associated with poor outcome in
lymph node–positive tumors.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 5 : 8765 | DOI: 10.1038/srep08765 4
Methods
Patient Cohort and Tissue Microarray (TMA). Appropriate Institutional Review
Board (IRB) approval from the Indiana University Research Ethics Committee was
obtained. The methods were carried out in "accordance" with the approved IRB
guidelines; informed consent was obtained from all subjects. A TMAwas constructed
from 133 consecutive patients with breast cancer. The procedure involved extracting
1 mm punches from tumors and implanting them in a new paraffin block. The array
information was recorded in an Excel sheet. The cohort consists of 133 women with
diagnosed with invasive carcinoma in the same year. The TMAwas constructed using
duplicate 1 mm cores from tumors. Clinical data with respect to age, tumor size, and
ER and HER2 expression status were collected from the clinical charts. The ER and
HER2 analyses were performed in a CLIA-certified lab using cutoffs recommended
by the current ASCO-CAP guidelines34,35. All patients had undergone some form of
nodal assessment (either sentinel node biopsy or axillary nodal sampling); none had
received neoadjuvant chemotherapy.
RNA In Situ Hybridization Assay (RNA ISH). In situ detection for HOTAIR was
performed using the RNAscope (Brown) FFPE kit (Advanced Cell Diagnostics,
Hayward, CA) according to the manufacturer’s instructions. Briefly, TMAs were cut
in 4 mm thick sections. The tissue was baked for 1 hour at 60uC. The samples were
then placed in Cytosol and brought down to water. Solution 1 was applied for
15 minutes at room temperature. The tissue sections were boiled at 95uC for
15 minutes in solution 2. Solution 3 (protease treatment) was then applied at 40uC.
The provided probe and probe solution were applied. The slides were covered with
agarose gel and placed in a rack at 40uC for hybridization for 2 hours. The tissue
samples were then washed in the provided washing buffer. The 3,39-
diaminobenzidine solutions A and B were mixed in equal volume and left on for
10 minutes at room temperature. Hematoxylin counterstaining was performed.
A provided positive control probe ubiquitin C was used. For negative control, the
enclosed negative control probe was applied. In addition, samples where the probe
was omitted were included to exclude background staining.
The slides were independently evaluated by two separate observers (ITV and SB).
Positive staining was indicated by signals as brown punctate dots present in the
nucleus and/or cytoplasm as described in prior studies26. The number of signal
staining was counted in 100 tumor cells. The study was performed on tissue micro-
arrays (TMAs) which had 1 mm cores. This relatively small tissue core in many ways
circumvented issues related to hotspots and tissue heterogeneity. The number 100
was chosen to ensure good representation of the tumor without loss of ‘‘huge’’
number of cases. The continuous number was categorized into four categories for
statistical analysis. These categories were 05 less than 1 signal per 100 cells; 15 1–10
signals; 2 5 11–100 signals, and 3 5. 101 signals in 100 cells.
The expression of the HOTAIR lincRNA was primarily correlated with nodal
status. The secondary endpoints included correlations with other clinicopathological
parameters such as age, tumor size, grade, and ER, PR, and HER2 expression status.
Analysis of The Cancer Genome Atlas (TCGA). To validate the clinical relevance of
HOTAIR levels in a larger cohort of breast cancer, we obtained the normalized levels
ofHOTAIR expression (Level 3 data) in 952 breast cancer patients enrolled in TCGA
database breast invasive carcinoma study (available at https://tcga-data.nci.nih.gov/
tcga/tcgaHome2.jsp). Patients with breast cancer were categorized based on the ER
status (n 5 924; 656 ER positive), HER2 (n 5 336; 145 HER2 positive), and lymph
node status. The clinical information for each patient was also obtained. To model
survival, gene expression at or below median was considered low and above median
was considered high. Overall survival was calculated from the date of initial diagnosis
of breast cancer to disease-specific deaths (patients whose vital status is termed dead)
and months to last followup (patients who are alive). Kaplan–Meier survival analysis
was used to estimate association ofHOTAIR expression with survival of patients and
with ER, HER2, and nodal status. The ‘‘survival’’ package in R (R Foundation for
Statistical Computing) was used for statistical analyses.
Statistical Analysis. Data were analyzed using Statistical Package for Social Sciences
v.17.0 (SPSS Institute, Chicago, IL, USA) software to determine the correlations
between HOTAIR and multiple clinicopathological parameters. Fisher exact test and
chi-squared test were performed. All P values were two-sided, and 0.05 was taken as
the significance level. Survival analyses by Kaplan–Meier method were performed for
both epithelial and stromal cells as appropriate. The differences in survival were tested
using the Log rank test.
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